BioXcel Therapeutics, Inc. Effective Income Tax Rate Reconciliation, Tax Credit, Percent
BioXcel Therapeutics, Inc. (BTAI) reported Effective Income Tax Rate Reconciliation, Tax Credit, Percent of -3.20% for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-28.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits · last filed 2025-03-28
- BioXcel Therapeutics, Inc. effective income tax rate reconciliation, tax credit, percent for fiscal 2024 was -3.20%.
- BioXcel Therapeutics, Inc. effective income tax rate reconciliation, tax credit, percent for fiscal 2023 was -2.30%, a 209.52% decline from fiscal 2022.
- BioXcel Therapeutics, Inc. effective income tax rate reconciliation, tax credit, percent for fiscal 2022 was 2.10%, a 0.00% change from fiscal 2021.
- BioXcel Therapeutics, Inc. effective income tax rate reconciliation, tax credit, percent for fiscal 2021 was 2.10%, a 43.24% decline from fiscal 2020.
| Period end | Effective Income Tax Rate Reconciliation, Tax Credit, Percent 12 month | Effective Income Tax Rate Reconciliation, Tax Credit, Percent 12 month as first filed |
|---|---|---|
| 2024-12-31 | -3.20% 10-K · filed 2025-03-28 | |
| 2023-12-31 | -2.30% 10-K · filed 2025-03-28 | 2.30% 10-K · filed 2024-03-22 |
| 2022-12-31 | 2.10% 10-K · filed 2024-03-22 | |
| 2021-12-31 | 2.10% 10-K · filed 2023-03-16 | |
| 2020-12-31 | 3.70% 10-K · filed 2022-03-11 | |
| 2019-12-31 | 2.70% 10-K · filed 2021-03-12 | |
| 2018-12-31 | 1.60% 10-K · filed 2020-03-09 | |
| 2017-12-31 | 0.90% 10-K · filed 2019-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |